Interferon alpha-2a in cutaneous T-cell lymphoma

M. L. Vegna, G. Papa, D. Defazio, F. Pisani, G. Coppola, O. De Pita, P. Puddu, G. Ferranti, R. Simoni, F. Mandelli

Research output: Contribution to journalArticle

Abstract

23 newly diagnosed patients affected by cutaneous T-cell lymphoma were treated with sub-cutaneous interferon alpha-2a to evaluate the therapeutic efficacy and the toxicity of this agent. IFN was administered daily with dose escalation from 3 to 18 million units for 12 weeks; thereafter, patients induced into complete (CR) or partial (PR) remission were given IFN at maximal tolerated dose 3 times weekly for 6 or 9 months. The objective tumor response was observed in 17 patients (74%): 8 (35%) were CR and 9 (39%) were PR. A 74-yr-old patient died because of neutropenia and sepsis at the end of induction phase, while receiving IFN at dose of 18 million units. Disease stage is the initial feature predictive of response to IFN therapy. The dose schedule of this study was well tolerated: only 3 patients developed liver toxicity, while leukopenia was evident in 6 patients. Only 2 CR patients have relapsed, 18 and 24 months from response; the remaining 6 CR patients are in continuous complete remission with a median follow-up of 41.8 months. 6 PR patients have progressed from 8 to 17 months after response, and in the 3 PR patients not yet progressed the response duration ranges from 20 to 24 months. In conclusion, interferon alpha-2a is a very effective agent in therapy of untreated cutaneous T-cell lymphoma with an overall response rate of 74%.

Original languageEnglish
Pages (from-to)32-35
Number of pages4
JournalEuropean Journal of Haematology, Supplement
Volume45
Issue number52
Publication statusPublished - 1990

Fingerprint

Cutaneous T-Cell Lymphoma
interferon alfa-2a
Maximum Tolerated Dose
Leukopenia
Neutropenia
Sepsis
Appointments and Schedules
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Vegna, M. L., Papa, G., Defazio, D., Pisani, F., Coppola, G., De Pita, O., ... Mandelli, F. (1990). Interferon alpha-2a in cutaneous T-cell lymphoma. European Journal of Haematology, Supplement, 45(52), 32-35.

Interferon alpha-2a in cutaneous T-cell lymphoma. / Vegna, M. L.; Papa, G.; Defazio, D.; Pisani, F.; Coppola, G.; De Pita, O.; Puddu, P.; Ferranti, G.; Simoni, R.; Mandelli, F.

In: European Journal of Haematology, Supplement, Vol. 45, No. 52, 1990, p. 32-35.

Research output: Contribution to journalArticle

Vegna, ML, Papa, G, Defazio, D, Pisani, F, Coppola, G, De Pita, O, Puddu, P, Ferranti, G, Simoni, R & Mandelli, F 1990, 'Interferon alpha-2a in cutaneous T-cell lymphoma', European Journal of Haematology, Supplement, vol. 45, no. 52, pp. 32-35.
Vegna ML, Papa G, Defazio D, Pisani F, Coppola G, De Pita O et al. Interferon alpha-2a in cutaneous T-cell lymphoma. European Journal of Haematology, Supplement. 1990;45(52):32-35.
Vegna, M. L. ; Papa, G. ; Defazio, D. ; Pisani, F. ; Coppola, G. ; De Pita, O. ; Puddu, P. ; Ferranti, G. ; Simoni, R. ; Mandelli, F. / Interferon alpha-2a in cutaneous T-cell lymphoma. In: European Journal of Haematology, Supplement. 1990 ; Vol. 45, No. 52. pp. 32-35.
@article{e7015ef2e78f48118568b7edcef7a4ba,
title = "Interferon alpha-2a in cutaneous T-cell lymphoma",
abstract = "23 newly diagnosed patients affected by cutaneous T-cell lymphoma were treated with sub-cutaneous interferon alpha-2a to evaluate the therapeutic efficacy and the toxicity of this agent. IFN was administered daily with dose escalation from 3 to 18 million units for 12 weeks; thereafter, patients induced into complete (CR) or partial (PR) remission were given IFN at maximal tolerated dose 3 times weekly for 6 or 9 months. The objective tumor response was observed in 17 patients (74{\%}): 8 (35{\%}) were CR and 9 (39{\%}) were PR. A 74-yr-old patient died because of neutropenia and sepsis at the end of induction phase, while receiving IFN at dose of 18 million units. Disease stage is the initial feature predictive of response to IFN therapy. The dose schedule of this study was well tolerated: only 3 patients developed liver toxicity, while leukopenia was evident in 6 patients. Only 2 CR patients have relapsed, 18 and 24 months from response; the remaining 6 CR patients are in continuous complete remission with a median follow-up of 41.8 months. 6 PR patients have progressed from 8 to 17 months after response, and in the 3 PR patients not yet progressed the response duration ranges from 20 to 24 months. In conclusion, interferon alpha-2a is a very effective agent in therapy of untreated cutaneous T-cell lymphoma with an overall response rate of 74{\%}.",
author = "Vegna, {M. L.} and G. Papa and D. Defazio and F. Pisani and G. Coppola and {De Pita}, O. and P. Puddu and G. Ferranti and R. Simoni and F. Mandelli",
year = "1990",
language = "English",
volume = "45",
pages = "32--35",
journal = "Scandinavian journal of haematology. Supplementum",
issn = "0902-4506",
publisher = "Wiley-Blackwell",
number = "52",

}

TY - JOUR

T1 - Interferon alpha-2a in cutaneous T-cell lymphoma

AU - Vegna, M. L.

AU - Papa, G.

AU - Defazio, D.

AU - Pisani, F.

AU - Coppola, G.

AU - De Pita, O.

AU - Puddu, P.

AU - Ferranti, G.

AU - Simoni, R.

AU - Mandelli, F.

PY - 1990

Y1 - 1990

N2 - 23 newly diagnosed patients affected by cutaneous T-cell lymphoma were treated with sub-cutaneous interferon alpha-2a to evaluate the therapeutic efficacy and the toxicity of this agent. IFN was administered daily with dose escalation from 3 to 18 million units for 12 weeks; thereafter, patients induced into complete (CR) or partial (PR) remission were given IFN at maximal tolerated dose 3 times weekly for 6 or 9 months. The objective tumor response was observed in 17 patients (74%): 8 (35%) were CR and 9 (39%) were PR. A 74-yr-old patient died because of neutropenia and sepsis at the end of induction phase, while receiving IFN at dose of 18 million units. Disease stage is the initial feature predictive of response to IFN therapy. The dose schedule of this study was well tolerated: only 3 patients developed liver toxicity, while leukopenia was evident in 6 patients. Only 2 CR patients have relapsed, 18 and 24 months from response; the remaining 6 CR patients are in continuous complete remission with a median follow-up of 41.8 months. 6 PR patients have progressed from 8 to 17 months after response, and in the 3 PR patients not yet progressed the response duration ranges from 20 to 24 months. In conclusion, interferon alpha-2a is a very effective agent in therapy of untreated cutaneous T-cell lymphoma with an overall response rate of 74%.

AB - 23 newly diagnosed patients affected by cutaneous T-cell lymphoma were treated with sub-cutaneous interferon alpha-2a to evaluate the therapeutic efficacy and the toxicity of this agent. IFN was administered daily with dose escalation from 3 to 18 million units for 12 weeks; thereafter, patients induced into complete (CR) or partial (PR) remission were given IFN at maximal tolerated dose 3 times weekly for 6 or 9 months. The objective tumor response was observed in 17 patients (74%): 8 (35%) were CR and 9 (39%) were PR. A 74-yr-old patient died because of neutropenia and sepsis at the end of induction phase, while receiving IFN at dose of 18 million units. Disease stage is the initial feature predictive of response to IFN therapy. The dose schedule of this study was well tolerated: only 3 patients developed liver toxicity, while leukopenia was evident in 6 patients. Only 2 CR patients have relapsed, 18 and 24 months from response; the remaining 6 CR patients are in continuous complete remission with a median follow-up of 41.8 months. 6 PR patients have progressed from 8 to 17 months after response, and in the 3 PR patients not yet progressed the response duration ranges from 20 to 24 months. In conclusion, interferon alpha-2a is a very effective agent in therapy of untreated cutaneous T-cell lymphoma with an overall response rate of 74%.

UR - http://www.scopus.com/inward/record.url?scp=0025619183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025619183&partnerID=8YFLogxK

M3 - Article

C2 - 2279544

AN - SCOPUS:0025619183

VL - 45

SP - 32

EP - 35

JO - Scandinavian journal of haematology. Supplementum

JF - Scandinavian journal of haematology. Supplementum

SN - 0902-4506

IS - 52

ER -